Comparison
Buserelin vs. DSIP
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
57982-77-1
62568-57-4
Molecular weight
1239.42 g/mol
848.81 g/mol
Half-life
no data
0.1 h
Sequence
no data
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluMechanism of action
Buserelin
Buserelin is a potent GnRH agonist: after an initial stimulatory surge ('flare'), continuous receptor occupancy causes downregulation and thereby suppression of LH, FSH and the downstream sex hormones.
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
0
4
of which in humans
0
1
Effects recorded
2
3
Open conflicts
0
1
Documented adverse events
1
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Buserelin and DSIP?
- Buserelin is classified as "Research other", while DSIP is classified as "Research other". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. DSIP: Synthetic nonapeptide isolated in 1977 by Guido Monnier and Marcel Schoenenberger from the blood of rabbits in delta sleep. Despite the name, the role in sleep regulation is contested and not confirmed by Western RCTs in larger populations. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Buserelin or DSIP?
- The highest available evidence level is "Human RCT" for Buserelin and "Human trial" for DSIP. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Buserelin and DSIP in Germany and the United States?
- Germany: Buserelin — Prescription, DSIP — Unapproved. United States: Buserelin — Unapproved, DSIP — Unapproved. These are factual summaries with source and review date on the individual pages.